# Humana (HUM) financials

Humana reported revenue of $129.7 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 10.1% from fiscal 2024. Net income was $1.19 billion and diluted earnings per share $9.84.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $41.2 billion, up 26.1% from a year earlier.

Source: Humana's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 6 Nov 2026. Amounts in USD. Page: https://aapwire.com/stocks/HUM. Retrieved 2026-11-16.

## Latest results: Q3 FY2026

Humana reported revenue of $41.2 billion, up 26.1% from a year earlier, net income of $162 million and diluted earnings per share of $1.33 against $1.62 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, filed 6 Nov 2026.

| Measure | Q3 FY2026 | Q3 FY2025 | Change |
| --- | ---: | ---: | ---: |
| Revenue | $41.16B | $32.65B | +26.1% |
| Operating income | $75.00M | $400.0M | −81.3% |
| Operating margin | 0.2% | 1.2% | −1.0 pts |
| Net income | $162.0M | $195.0M | −16.9% |
| Diluted EPS | $1.33 | $1.62 | −17.9% |
| Operating cash flow | $2.16B | $971.0M | +123% |
| Capital expenditure | $137.0M | $135.0M | +1.5% |
| Free cash flow | $2.03B | $836.0M | +142% |

Page: https://aapwire.com/stocks/HUM/earnings

## Annual figures (fiscal years)

| Measure | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $54.38B | $53.77B | $56.91B | $64.89B | $77.16B | $83.06B | $92.87B | $106.4B | $117.8B | $129.7B |
| Revenue growth | +0.2% | −1.1% | +5.8% | +14.0% | +18.9% | +7.7% | +11.8% | +14.5% | +10.7% | +10.1% |
| Operating income | $1.74B | $4.26B | $3.10B | $3.19B | $4.99B | $3.15B | $3.80B | $4.01B | $2.56B | $2.70B |
| Net income | $614.0M | $2.45B | $1.68B | $2.71B | $3.37B | $2.93B | $2.81B | $2.49B | $1.21B | $1.19B |
| Diluted EPS | $4.07 | $16.81 | $12.16 | $20.10 | $25.31 | $22.67 | $22.08 | $20.00 | $9.98 | $9.84 |
| Operating cash flow | $1.94B | $4.05B | $2.17B | $5.28B | $5.64B | $2.26B | $4.59B | $3.98B | $2.97B | $921.0M |
| Capital expenditure | $527.0M | $524.0M | $612.0M | $736.0M | $964.0M | $1.34B | $1.14B | $1.00B | $575.0M | $546.0M |
| Free cash flow | $1.41B | $3.53B | $1.56B | $4.55B | $4.67B | $920.0M | $3.45B | $2.98B | $2.39B | $375.0M |
| Operating margin | 3.2% | 7.9% | 5.4% | 4.9% | 6.5% | 3.8% | 4.1% | 3.8% | 2.2% | 2.1% |
| Net margin | 1.1% | 4.6% | 3.0% | 4.2% | 4.4% | 3.5% | 3.0% | 2.3% | 1.0% | 0.9% |
| Cash and equivalents | $3.88B | $4.04B | $2.34B | $4.05B | $4.67B | $3.39B | $5.06B | $4.69B | $2.22B | $4.20B |
| Total debt | $4.09B | $4.92B | $6.07B | $6.11B | $7.14B | $13.22B | $11.73B | $12.25B | $12.24B | $12.91B |
| Shareholders' equity | $10.69B | $9.84B | $10.16B | $12.04B | $13.73B | $16.08B | $15.31B | $16.26B | $16.38B | $17.66B |
| Diluted shares | 151M | 146M | 138M | 135M | 133M | 129M | 127M | 124M | 121M | 121M |
| Dividends per share | $1.16 | $1.49 | $1.90 | $2.15 | $2.43 | $2.73 | $3.06 | $3.44 | $3.54 | $3.54 |

## Quarterly figures (last eight fiscal quarters)

| Measure | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $29.21B | $32.11B | $32.39B | $32.65B | $32.52B | $39.65B | $40.87B | $41.16B |
| Revenue, year on year | +10.4% | +8.4% | +9.6% | +11.1% | +11.3% | +23.5% | +26.2% | +26.1% |
| Operating income | −$543.0M | $2.01B | $1.10B | $400.0M | −$808.0M | $1.75B | $1.36B | $75.00M |
| Net income | −$693.0M | $1.24B | $545.0M | $195.0M | −$796.0M | $1.19B | $694.0M | $162.0M |
| Diluted EPS | −$5.74 | $10.30 | $4.51 | $1.62 | −$6.58 | $9.83 | $5.73 | $1.33 |
| Free cash flow | −$682.0M | $236.0M | $1.16B | $836.0M | −$1.85B | $1.13B | $1.83B | $2.03B |

## Operating KPIs

| KPI | Latest | Period | Change on a year |
| --- | ---: | --- | --- |
| [Premiums and services revenue detail (State-based contracts and other · Insurance)](https://aapwire.com/stocks/HUM/kpi/premiums-and-services-revenue-detail-state-based-contracts-and-other-insurance) | 3,641 | quarter to 30 Sep 2026 | down 2.4% |
| [Home Solutions episodic admissions](https://aapwire.com/stocks/HUM/kpi/home-solutions-episodic-admissions) | 85,650 | quarter to 31 Mar 2026 | up 4.3% |
| [PPO/PFFS individual medicare advantage membership](https://aapwire.com/stocks/HUM/kpi/ppo-pffs-individual-medicare-advantage-membership) | 3,237.0 | at 30 Sep 2026 | up 23.9% |
| [CenterWell, Pharmacy solutions premiums and services revenue detail](https://aapwire.com/stocks/HUM/kpi/centerwell-pharmacy-solutions-premiums-and-services-revenue-detail) | $3,793 | quarter to 30 Jun 2026 | up 21.0% |
| [CenterWell, Primary care premiums and services revenue detail](https://aapwire.com/stocks/HUM/kpi/centerwell-primary-care-premiums-and-services-revenue-detail) | $2,008 | quarter to 30 Jun 2026 | up 35.8% |
| [CenterWell, Home solutions premiums and services revenue detail](https://aapwire.com/stocks/HUM/kpi/centerwell-home-solutions-premiums-and-services-revenue-detail) | $989 | quarter to 30 Jun 2026 | up 7.2% |
| [CenterWell premiums and services revenue detail](https://aapwire.com/stocks/HUM/kpi/centerwell-premiums-and-services-revenue-detail) | $6,790 | quarter to 30 Jun 2026 | up 22.6% |
| [Mail-Order penetration (Pharmacy Solutions, Total Medicare)](https://aapwire.com/stocks/HUM/kpi/mail-order-penetration-pharmacy-solutions-total-medicare) | 23.8% | quarter to 31 Mar 2026 | down 2.2 points |
| [External Revenues](https://aapwire.com/stocks/HUM/kpi/external-revenues) | $40.8B | quarter to 30 Sep 2026 | up 26.4% |
| [Services revenue](https://aapwire.com/stocks/HUM/kpi/services-revenue) | $2.1B | quarter to 30 Sep 2026 | up 32.8% |
| [Insurance revenue](https://aapwire.com/stocks/HUM/kpi/insurance-revenue) | $39.1B | quarter to 30 Sep 2026 | up 25.3% |
| [CenterWell revenue](https://aapwire.com/stocks/HUM/kpi/centerwell-revenue) | $7.2B | quarter to 30 Sep 2026 | up 21.7% |

## Method

Each period is read from the report the company filed and checked against accounting identities; a figure that does not pass is left blank (—), never estimated. Free cash flow is operating cash flow less capital expenditure. Diluted EPS is as the company reported it, adjusted for later stock splits. Research information only, not investment advice.
